- Home
- PPHC vs EBS Comparison
PPHC vs EBS Comparison
Compare PPHC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPHC | EBS |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | 447 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.4M | 411.1M |
| IPO Year | 2026 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PPHC | EBS |
|---|---|---|
| Price | $14.06 | $8.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 77.7K | ★ 611.9K |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | N/A | ★ 0.93 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.62 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.25 | $4.71 |
| 52 Week High | $14.50 | $14.06 |
Technical Indicators
Market Signals| Indicator | PPHC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 44.22 |
| Support Level | $11.53 | $7.73 |
| Resistance Level | $14.25 | $8.54 |
| Average True Range (ATR) | 0.65 | 0.33 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 71.15 | 18.38 |
Price Performance
Historical ComparisonAbout PPHC Public Policy Holding Company Inc. Common Stock
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.